ABSTRACT
INTRODUCTION
Precise and standardized assessment of disease progression and treatment response is critical to the design of multiple sclerosis (MS) clinical studies. The Expanded Disability Status Scale (EDSS) 1 has long been considered the goldstandard measurement of disability and disease progression in MS. 2 The EDSS measures neurologic impairment across 8 functional systems 1 and is used routinely as a primary or secondary clinical end point in studies of disease-modifying therapies (DMTs). [3] [4] [5] [6] [7] [8] Scoring on the EDSS ranges from 0 (normal neurologic examination) to 10.0 (death). Intermediate scores indicate minimal disability (1.0 -3.0), moderate disability (3.0 -5.0), and more severe disability, such as needing assistance walking (Ն6.0) and bedbound status (Ն8.5). 1 Despite its widespread use, the EDSS has several limitations, including the need for a neurologist to examine the patient and derive the score. At the lower end of the scale (scores Ͻ3.0), the score is derived by rating the severity of impairments determined by neurologic examination to obtain multiple functional systems scores. At that range of the scale, the EDSS becomes imprecise because of subjectivity in determining the scores; it has been argued that the scale does not measure disability at the lower end. In the middle and upper regions of the scale (scores Ն3.0), the EDSS is weighted heavily toward ambulatory disability and is less sensitive to other dimensions of MS such as arm and cognitive function. Nonlinearity, in which a 1.0-point change at 1 point on the scale is not the same as a 1.0-point change at another point on the scale, is another drawback to the use of the EDSS. In some clinical studies, patients with mild to moderate disability (EDSS score Ͻ6.0) were grouped with more severely disabled patients (EDSS score Ն6.0), and disease progression was defined as a 1.0-or 0.5-point change. One study 2 challenged the notion that these changes were similar and found that a 0.5-point change in EDSS score for more severely disabled patients did not correspond with changes in other instruments that rated disability. In contrast, changes in the EDSS for patients with mild to moderate disease severity more closely corresponded with other outcome measures. These findings suggest that the EDSS is less responsive to changes in more severely ill patients. 2 In 1994, the US National Multiple Sclerosis Society convened a task force to develop a multidimensional clinical rating instrument that (1) reflected the varied clinical expression of MS across patients and over time, (2) evaluated each dimension independently of the others, and (3) measured cognitive function and other dimensions not included in other instruments available at the time. The result was the Multiple Sclerosis Functional Composite (MSFC), which is simple to administer regardless of the physician's or technician's prior experience, relevant to clinical studies (i.e., sensitive, reliable, and quantitative), and supplementary to the EDSS. [9] [10] [11] [12] Herein, we examine the MSFC, discuss its advantages and limitations, and review its use in clinical studies of DMTs in MS.
COMPONENTS OF THE MSFC
The MSFC is made up of 3 components that measure arm and hand dexterity, walking speed, and cognition (table 1) . 9 The 9-Hole Peg Test (9HPT) measures arm and hand function according to the time needed for the patient to insert and remove 9 pegs from a board, first with the dominant hand and then with the nondominant hand. The final score is recorded as the mean time for both hands. The 9HPT is more sensitive than the EDSS in detecting deteriorations in upper extremity function. 9, 13 The Timed 25-Foot Walk (T25FW) assesses change in ambulatory function. A time increase of 20% or greater indicates a clinically meaningful impairment in gait. 9, 14 The Paced Auditory Serial Addition Test (PASAT) is a measure of cognitive function in which patients listen to a series of 61 spoken numbers separated by 3-second (PASAT3) or 2-second (PASAT2) intervals. Each number must be added to the prior number. The final score is the number of correct additions in the series. 9, 15 Because practice effects have been well described, particularly for the 9HPT and the PASAT3, a run-in to establish a stable baseline is necessary. [16] [17] [18] The 3 components of the MSFC are partially independent of each other and correlate to a similar extent with the composite score. 19 Because the components differ in direction of change (deterioration indicated by higher scores on the 9HPT and T25FW vs lower scores on the PASAT3) and units of measurement (time vs number correct), the MSFC composite score is reported as a Z-score that is computed from individual Z-scores for each component. Lower MSFC scores compared with baseline or prior measurements indicate neurologic deterioration. 17 A Z-score is a standardized score that compares a patient's performance with that of a reference population. Z-scores are the number of standard deviations between scores for the individual and the reference population. 9 The reference population used to create Z-scores can be derived from a standard MS population such as the pooled dataset used to develop the MSFC, 9 the entry scores from patients enrolled in a particular study, or healthy controls. Choice of the reference population (e.g., patients with MS vs healthy controls) will influence weighting of the individual components.
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RELIABILITY AND VALIDITY OF THE MSFC
The MSFC was used as the primary efficacy end point in the International Multiple Sclerosis Secondary Progressive Avonex Controlled Trial. 17 Intrarater reliability was tested after the MSFC was administered 3 times before baseline and at baseline. Intraclass correlation coefficients of 0.90 for session 3 compared with session 4 and 0.87 for all 4 sessions combined indicate excellent intrarater reliability. Interrater reliability after 6 months without testing/ retraining also was excellent, with an intraclass correlation coefficient of 0.96. The MSFC has been validated by different investigators and in different patient populations. Construct validity is the ability of an instrument to measure adequately the disease dimensions that it was designed to measure. 21 In other words, scores on any given rating scale should, for example, indicate deterioration over time for patients with progressive disease and improvement for patients who respond to treatment. In a cross-sectional study, 22 MSFC Z-scores were lower (indicating a higher level of disability) in patients with primary progressive MS (Ϫ0.4) or secondary progressive MS (Ϫ0.3) vs patients with relapsing-remitting MS (RRMS) (ϩ0.42; p Ͻ 0.05).
Concurrent validity is an assessment of the level of correlation between the instrument under development and other accepted or validated instruments. Moderate to moderately strong correlations between MSFC and EDSS scores indicate some commonality between these scales in their assessment of disability (table 2) . One relatively consistent finding across studies was that walking time (but not arm function or cognition) correlates strongly with the EDSS, which is not unexpected given the bias of the EDSS toward ambulation. 9, 17, 22, 23 Thus, the MSFC is a good measure of ambulatory disability, and it also includes aspects of neurologic function (e.g., arm function and cognition) not measured well by the EDSS.
One study 24 compared the MSFC with the EDSS and several different quality of life instruments, including the Sickness Impact Profile (SIP), in 300 patients with MS. The MSFC correlated relatively strongly with the EDSS (r ϭ Ϫ0.80) and the overall SIP score (r ϭ Ϫ0.62). Correlations between the MSFC, the physical component of the SIP (r ϭ Ϫ0.71), and the physical component summary of the Medical Outcomes Study Short Form (SF-36) (r ϭ 0.41) were stronger than those for the SIP psychosocial score (r ϭ Ϫ0.34) or the SF-36 mental component summary (r ϭ Ϫ0.05).
Concurrent validity of the MSFC also has been shown with MRI findings. Several traditional and nontraditional MRI measures, including T1 and T2 lesion load, brain atrophy, magnetic transference ratio, and mean diffusivity, correlated modestly (r Ͻ0.50) but significantly with MSFC scores. [25] [26] [27] [28] [29] [30] [31] [32] [33] Scores on the 9HPT correlated with functional MRI measures of motor cortex. 30 Baseline MSFC scores in patients with RRMS were predictive of brain atrophy 2 and 8 years later. 31, 32 In addition, other studies have shown that MSFC scores correlated with metabolic and immunologic markers of disease severity in the brain [34] [35] [36] and chemokine polymorphisms associated with MS.
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ADVANTAGES AND LIMITATIONS OF THE
MSFC The MSFC was developed as a measure of neurologic impairment that would improve on or supplement information gleaned from the EDSS. Because the MSFC can be administered by trained office staff 38 rather than a neurologist, it should be less expensive and more convenient to use than the EDSS. The MSFC is a quantitative instrument that uses linear measures resulting in comparable changes across the range of disease severity. In contrast, the EDSS is based on qualitative psychometrics (i.e., an ordinal scale), and deterioration over the range of the scale is nonlinear, resulting in a ceiling effect. 1, 2, 19 Unlike the EDSS, the MSFC includes an assessment of cognitive function and thus measures a broader range of dimensions of disability. 9 Finally, results from a prospective study 39 showed that the MSFC more precisely measures between-group changes than the EDSS in cohorts of patients with MRIdocumented differences in MS severity.
Limitations of the MSFC include the lack of a measure of vision. 9 Second, clinical interpretation of the MSFC Z-score change and individual component Z-score changes are difficult. Third, there are significant practice effects on the PASAT3 and the 9-HPT, which result in improving scores that can make interpretation difficult. 18 However, in parallelgroup studies, the practice and learning effects should be controlled. Fourth, use of particular reference populations introduces weightings to the different components of the MSFC, and this may limit the comparability of results from one study to another. 40 Finally, although a 20% change in scores on the T25FW and 9-HPT and a 0.5 SD change on the PASAT3 are considered clinically meaningful, 41 similar cut points for the overall MSFC score have not been characterized. 
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USE OF THE MSFC IN CLINICAL STUDIES
Interferon-␤-1a. The value of the MSFC in predicting future disability and MRI status in patients with RRMS was documented in an 8-year follow-up of a phase 3 study of IM interferon (IFN)␤-1a (Avonex). 31 In a subset of 159 patients, baseline MSFC scores modestly correlated with MSFC scores at 2 years (r ϭ 0.75) and 8 years (r ϭ 0.64); these correlations were stronger somewhat than those between baseline EDSS scores and 2-year (r ϭ 0.54) and 8-year (r ϭ 0.45) EDSS scores. Baseline MSFC scores and MSFC change scores (baseline to year 2) correlated with disability at 8 years (figure 1), and baseline MSFC and MSFC change scores over 2 years predicted severe EDSS scores (EDSS Ն6.0) at 8-year follow-up, with odds ratios of 2.72 (95% confidence interval [CI]: 1.42-5.21; p ϭ 0.002) and 3.05 (95% CI: 1.61-5.78; p Ͻ 0.001). Brain atrophy as measured by brain parenchymal fraction on MRI also correlated with MSFC scores at baseline (r ϭ 0.419; p Ͻ 0.0001), year 2 (r ϭ 0.498; p Ͻ 0.0001), and follow-up (r ϭ 0.481; p Ͻ 0.0001). 32 In a subset of 30 patients from this study population who were observed for 13 years, the change in T2 lesion volume from baseline to 2 years correlated with MSFC scores at the 13-year follow-up visit (r ϭ Ϫ0.50; p ϭ 0.005). 43 In the phase 3 International Multiple Sclerosis Secondary Progressive Avonex Controlled Trial in patients with secondary progressive MS, IM IFN␤-1a reduced deterioration in MSFC Z-scores by 40.4% (p ϭ 0.033) compared with placebo. 44 Over 2 years, changes in MSFC scores correlated with the change in SF-36 mental component summary scores (r ϭ 0.182; p Յ 0.01) in this study. 45 Interferon-␤-1b. The MSFC has been used as a secondary efficacy measure in a long-term study of subcutaneous IFN␤-1b (Betaseron) in patients with a first neurologic event suggestive of MS and 2 or more clinically silent MRI lesions. The Betaferon/Betaseron in Newly Emerging MS for Initial Treatment study compared IFN␤-1b treatment every other day (n ϭ 292) with placebo (n ϭ 176) for 2 years or until development of clinically evident MS. At that point, patients were eligible to continue openlabel IFN␤-1b (early treatment) or switch from placebo to active treatment (delayed treatment) for up to 3 additional years for a total of 5 years. An interim analysis conducted at the 3-year postrandomization point showed that the total MSFC score improved for all patients but that no significant differences were observed between the early-and delayedtreatment groups ( p ϭ 0.48). Differences between groups in favor of early treatment were noted on the PASAT (version not specified; p ϭ 0.011) but not on the 9HPT ( p ϭ 0.118) or the T25FW ( p ϭ 0.792). The authors concluded that the MSFC may not sufficiently be sensitive to detect change in patients with very early-stage disease. 46 In addition, the MSFC was used as a secondary outcome measure in the small pilot study of IFN␤-1b in patients with primary progressive MS (n ϭ 49) or transitional MS (n ϭ 24). 47 Patients were randomized to IFN␤-1b or placebo for 2 years. Treatment with IFN␤-1b resulted in significant benefit on MSFC scores compared with placebo at the 6-month follow-up (specific data not provided). Data for longer periods of treatment were not reported.
Glatiramer acetate. To date, the MSFC has not been used in randomized placebo-controlled trials of glatiramer acetate (Copaxone).
Natalizumab. The MSFC was used as a measure of disability progression in the phase 3 Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study of natalizumab (Tysabri) in patients with RRMS. 7 Natalizumab improved changes in MSFC Z-scores ( p Յ 0.003) at each time point measured from 12 to 120 weeks compared with placebo ( figure 2) . 48, 49 Changes in MSFC Z-scores were correlated with changes in EDSS scores from baseline to weeks 48 (r ϭ Ϫ0.157; p Ͻ 0.001) and 120 (r ϭ Ϫ0.27; p Ͻ 0.001). 50 In addition, natalizumab improved changes in the T25FW (p Ͻ 0.001), 9HPT (p Ͻ 0.001), and PASAT3 (p ϭ 0.005) Z-scores during the 2-year study compared with placebo ( figure 3) . 49 When disability was defined as a 20% or greater sustained reduction from baseline score, the 9HPT (hazard ratio [HR], 0.55; 95% CI: 0.36 -0.84; p ϭ 0.005) and T25FW (HR, 0.66; 95% CI: 0.49 -0.89; p ϭ 0.006) were more sensitive to the beneficial effects of natalizumab (vs placebo) during a 2-year time period than was the PASAT3 (HR, 0.78; 95% CI: 0.35-1.72; p ϭ 0.534).
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THE PASAT The MSFC is unique among the available instruments for assessing neurologic disability because it includes the PASAT, a separate measure of cognition. Cognitive impairment is an important dimension of MS-related disability that can negatively affect quality of life, occupational ability, and rehabilitation. However, measurement of cognitive deterioration can be challenging. Longitudinal PASAT data cannot be interpreted without a control group because of marked practice effects. Moreover, the natural history of the PASAT in MS is highly variable and may be influenced by patient motivation or prior training.
The PASAT was used in several clinical trials of DMTs as a component of the MSFC or as a standalone measure of cognitive function. The PASAT (both the 3-second and 2-second versions, administered . 51 IM IFN␤-1a prolonged the time to sustained deterioration in the PASAT processing rate compared with placebo ( p ϭ 0.023), and fewer patients treated with IM IFN␤-1a (19.5%) showed sustained deterioration vs placebo (36.6%). The PASAT was included in a cognitive testing battery in a phase 3 study of glatiramer acetate in patients with RRMS in which no statistically significant differences were observed between glatiramer acetate and placebo for any of the cognitive tests used (including the PASAT) after 2 years of treatment. 52 The PASAT was administered as part of the MSFC in the phase 3 AFFIRM study of natalizumab monotherapy. 49, 53 Significantly greater improvements in PASAT3 Z-scores were seen over 2 years in the natalizumab group compared with the placebo group (figure 3).
CONCLUSION
The MSFC is a reliable and wellvalidated instrument that was developed as a multidimensional quantitative measure of neurologic disability in MS. Moderately strong correlations between the MSFC and the EDSS have been demonstrated, especially for ambulation. In addition, scores on the MSFC strongly correlate with progression of MRI lesions, brain atrophy, biomarkers of MS, and quality of life measurements in patients with MS.
The MSFC enables measurement of arm/hand dexterity and cognitive function that are not measured by the EDSS. Another consideration in favor of the MSFC over the EDSS is that the MSFC can be administered by a trained technician rather than a neurologist, which can be expected to result in lower costs. Findings from several studies suggest that the MSFC is more sensitive than the EDSS, 31, 44 although there have been observations that the responsiveness and long-term predictive value of the MSFC and the EDSS are relatively weak. 54 In addition, clinically significant cut points for changes in the MSFC and its individual component scores, such as a 20% or greater reduction in scores, are not well characterized. Regulatory authorities require that primary clinical outcome measures demonstrate clinically meaningful changes, and currently this requirement poses a problem for the MSFC. Use and interpretation of the MSFC also may be limited by the effect of the reference population on weighting of the different MSFC components.
The MSFC has been incorporated into many recent clinical studies, and it is being used in many ongoing studies. IM IFN␤-1a and natalizumab have shown statistically significant benefits on MSFC composite scores in clinical studies. Over time and with more widespread use, the MSFC is expected to be further refined and to contribute increasingly to outcomes assessments in MS clinical trials. 
